(Q34405619)

2 August 2017

1 reference

title

Cyclin-dependent kinase inhibitors for treating cancer (English)

1 reference

2 August 2017

Toogood PL

1 reference

2 August 2017

publication date

1 November 2001

1 reference

Medicinal Research Reviews

2 August 2017

published in

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

487-498

1 reference

2 August 2017

1 reference

Cyclins and cell cycle checkpoints

21 January 2018

1 reference

Control of the cell cycle and apoptosis

21 January 2018

1 reference

Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle

21 January 2018

1 reference

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

Inhibitors of mammalian G1 cyclin-dependent kinases

21 January 2018

1 reference

The INK4 family of cell cycle inhibitors in cancer

21 January 2018

1 reference

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

Role of the retinoblastoma protein in the pathogenesis of human cancer

21 January 2018

1 reference

Inhibition of ras-induced proliferation and cellular transformation by p16INK4.

21 January 2018

1 reference

Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression

21 January 2018

1 reference

CDK inhibition and cancer therapy

21 January 2018

1 reference

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

21 January 2018

1 reference

UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line

21 January 2018

1 reference

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

21 January 2018

1 reference

6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity.

21 January 2018

1 reference

Inhibition of cyclin-dependent kinases by purine analogues

21 January 2018

1 reference

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

21 January 2018

1 reference

Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors

21 January 2018

1 reference

Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity

21 January 2018

1 reference

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

21 January 2018

1 reference

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

21 January 2018

The Cell Cycle: A Review

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.1021

1 reference

2 August 2017

1 reference